QHP Capital announced an investment in Vector Clinical Trials, a leading clinical research site network led by Founder Dr. Bobby Mocherla.
The partnership is designed to accelerate Vector’s growth while preserving the qualities that have made the Company so successful to date – an unwavering focus on high-quality research that integrates into the physician and patient communities Vector serves, combining superior patient experience with high-velocity, representative enrollment.
Health Technology Insights: Baxter Earns HIRC Gold Resiliency Badge for IV and Nutrition Solutions
“Vector’s model starts with the community,” said Michael Sorensen, Partner at QHP Capital. “By partnering with physicians where patients already receive care, Vector consistently delivers speed, quality, and access – especially for populations historically underrepresented in research. We’re excited to back Dr. Bobby and invest behind building sites with real scale that serve their communities while meeting sponsors’ enrollment and data-quality needs.”
Health Technology Insights: AstraZeneca Launches US Direct-to-Consumer Medication Platform
“Our mission is to bring clinical research to patients where they are,” said Dr. Bobby Mocherla, Founder of Vector Clinical Trials. “QHP shares our patient-first philosophy and brings the pharma services expertise to help us expand responsibly – improving access, delivering high-performance enrollment across all demographics, and supporting our partners with best-in-class clinical operations.”
Cantor Fitzgerald served as financial advisor to Vector.
Health Technology Insights: Applied Policy Welcomes Cheryl Powell as Vice President of Health Policy
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
